A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution

被引:18
作者
Holloway, PA
Kaldenhoven, N
Kok-Schoemaker, HM
van Dijk, M
Otten, HG
Tilanus, M
Postma, S
Mutis, T
Lokhorst, HM
Bloem, AC
机构
[1] UMCU, Dept Immunol, NL-3584 CX Utrecht, Netherlands
[2] UMCU, Dept Haematol, NL-3584 CX Utrecht, Netherlands
[3] UMCU, Dept Pathol, NL-3584 CX Utrecht, Netherlands
关键词
myeloma; graft-versus-myeloma; minor histocompatibility antigen;
D O I
10.1111/j.1365-2141.2004.05283.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Following a human leucocyte antigen (HLA)-identical allogeneic stem cell transplantation (allo-SCT), minor histocompatibility antigens (mHags) play an important role in the induction of graft-versus-leukaemia (GvL) and graft-versus-myeloma (GvM). Many mHags show ubiquitous tissue expression and are associated with GvL and graft-versus-host disease. Here we describe a cytotoxic CD4(+) T lymphocyte line and a cytotoxic, CD4(+) T cell clone (CTC), 3AB11, which recognized a tissue-restricted mHag. This CTC was isolated from a multiple myeloma patient with clinical GvM following an HLA-matched allo-SCT. CTC 3AB11 was activated in a HLA-DP*0401 restricted fashion and the antigen was expressed by 27% of HLA-DP*0401 positive Epstein-Barr virus (EBV)-transformed B-cell lines (EBV-B). Tissue distribution analysis of antigen 3AB11 showed it to be expressed by patient-derived EBV-transformed B cell lines (EBVp), the myeloma plasma cell-line UM9 and monocytes. It was weakly expressed by peripheral blood-derived phytohaemagglutinin-induced T-cefl blasts and absent on CD40L stimulated peripheral B (CD40L B) cells and stromal cells. The relatively high prevalence of the HLA class II-restricted 3AB11 antigen, together with its apparent haematopoietic-restricted expression, makes it an antigen of interest for cellular immunotherapy.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 43 条
[1]   Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens [J].
Akatsuka, Y ;
Nishida, T ;
Kondo, E ;
Miyazaki, M ;
Taji, H ;
Iida, H ;
Tsujimura, K ;
Yazaki, M ;
Naoe, T ;
Morishima, Y ;
Kodera, Y ;
Kuzushima, K ;
Takahashi, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (11) :1489-1500
[2]   CD8+cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study [J].
Alyea, EP ;
Canning, C ;
Neuberg, D ;
Daley, H ;
Houde, H ;
Giralt, S ;
Champlin, R ;
Atkinson, K ;
Soiffer, RJ .
BONE MARROW TRANSPLANTATION, 2004, 34 (02) :123-128
[3]   Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant [J].
Alyea, EP ;
Soiffer, RJ ;
Canning, C ;
Neuberg, D ;
Schlossman, R ;
Pickett, C ;
Collins, H ;
Wang, YL ;
Anderson, KC ;
Ritz, J .
BLOOD, 1998, 91 (10) :3671-3680
[4]  
BAR BMAM, 1993, J CLIN ONCOL, V11, P513
[5]   Molecules and mechanisms of the graft-versus-leukaemia effect [J].
Bleakley, M ;
Riddell, SR .
NATURE REVIEWS CANCER, 2004, 4 (05) :371-380
[6]  
BLOEM A, 1988, J IMMUNOL, V140, P277
[7]   Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro:: studies with primary tumour cells and LTBMC-dependent cell lines [J].
Bloem, AC ;
Lamme, T ;
de Smet, M ;
Kok, H ;
Vooijs, W ;
Wijdenes, J ;
Boom, SE ;
Lokhorst, HM .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (01) :166-175
[8]   Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage [J].
Brouwenstijn, N ;
Slager, EH ;
Bakker, ABH ;
Schreurs, MWJ ;
Van der Spek, CW ;
Adema, GJ ;
Schrier, PI ;
Figdor, CG .
BRITISH JOURNAL OF CANCER, 1997, 76 (12) :1562-1566
[9]   The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma [J].
Brown, RD ;
Yuen, E ;
Nelson, M ;
Gibson, J ;
Joshua, D .
LEUKEMIA, 1997, 11 (08) :1312-1317
[10]   Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma [J].
Corradini, P ;
Cavo, M ;
Lokhorst, H ;
Martinelli, G ;
Terragna, C ;
Majolino, I ;
Valagussa, P ;
Boccadoro, M ;
Samson, D ;
Bacigalupo, A ;
Russell, N ;
Montefusco, V ;
Voena, C ;
Gahrton, G .
BLOOD, 2003, 102 (05) :1927-1929